Skip to main content

Correction to “Prior Authorization Required for Tarlatamab-dlle (Imdelltra) Effective November 1, 2024”

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.

This is a correction to the article titled “Prior Authorization Required for Tarlatamab-dlle (Imdelltra) Effective November 1, 2024,” which was published on this website on October 18, 2024.

In the “Requests for Initial Therapy” section, the word “hepatotoxicity” was missing from one of the signs and symptoms that a provider should monitor for.

The correct information is as follows:

  • Hepatotoxicity. Providers should monitor liver enzymes and bilirubin before each tarlatamab-dlle (Imdelltra) treatment.

For more information, call the TMHP Contact Center at 800-925-9126.